ICON Research gains a regulatory expert, plus new executives for Exco InTouch, Avillion and others.
ICON has appointed Mary Pendergast, a regulatory expert, to a non-executive role on its board of directors.
The new director is also president of Pendergast Consulting, a firm which provides communications advice to biopharmaceutical companies. Previously, she was Executive VP of Government Affairs at Irish drug firm Elan, and a deputy commissioner at the US FDA.
Ms. Pendergast is also a board member of AesRx, ARCH Foundation and Impax Laboratories.
Copyright - Unless otherwise stated all contents of this web site are © 2014 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
Recipharm, Catalent, INC and PRA completed eye-catching IPOs in 2014. Which firms are likely follow suit in 2015?
Catering for low value, high volume customers as well as the growing number of firms developing complex...
Clinverse, Intertek and inVentiv are among the pharma services companies announcing new staff this week.